◎ Sugi Atlas

Atlas / Drug / Oxaprozin

Oxaprozin

drug
On this page

Also known as CoxantoDayproNSC-310839OxaprozinaOxaprozineWY-21,743WY-21743SID11110656SID11110657SID26719634SID26747622SID4254158SID50106813SID50106814SID85230870SID90340983OxaprocinSID455291SID170464987

Summary

Oxaprozin (CHEMBL1071) is an approved small-molecule non-steroidal anti-inflammatory drug (ATC M01AE12) targeting PTGS1, PTGS2, and EPHX2; indicated across 4 conditions including rheumatic disorder and rheumatoid arthritis.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: M01AE12
  • Targets: 3 (PTGS1, PTGS2, EPHX2)
  • Indications: 4 conditions
  • Clinical trials: 1
  • Chemistry: 293.3 Da · C18H15NO3

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1071
NameOxaprozin
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID4614
ChEBICHEBI:7822
ATCM01AE12
Molecular formulaC18H15NO3
Molecular weight293.3
InChIKeyOFPXSFXSNFPTHF-UHFFFAOYSA-N

SMILES: C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3

IUPAC name: 3-(4,5-diphenyl-1,3-oxazol-2-yl)propanoic acid

ChEBI definition: A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.

Pharmacological roles (ChEBI): non-steroidal anti-inflammatory drug, analgesic.

Also known as: Coxanto, Daypro, NSC-310839, Oxaprozin, Oxaprozina, Oxaprozine, WY-21,743, WY-21743, SID11110656, SID11110657, SID26719634, SID26747622

Parent form; salt/anhydrous children: CHEMBL1200463

Patent coverage: 13,465 distinct patent families (51,044 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
PTGS1COX-1Inhibition5.660%P23219
PTGS2COX-2Inhibition4.440%P35354
EPHX2epoxide hydrolase 2Inhibition5.30%P34913

Broader ChEMBL bioactivity targets: 33 (assay-derived). Sample: Lysine-specific demethylase 4E, Nuclear receptor subfamily 4immunitygroup A member 1, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Peripheral myelin protein 22, ATP-binding cassette sub-family C member 4, Retinoic acid receptor RXR-beta, Nuclear receptor subfamily 4 group A member 3, Thyrotropin receptor.

Bioactivity

ChEMBL activities: 18 potent at pChembl ≥ 5 of 50 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
HTR2A7.08AC5083.7nMCHEMBL_ACT_25173534
ADRA1A7.03AC5092.6nMCHEMBL_ACT_25137799
PTGS26.96IC50110nMCHEMBL_ACT_19307253
HRH16.51AC50310nMCHEMBL_ACT_25212278
LMNA6.45Potency354.8nMCHEMBL_ACT_3665048
C56.19Kd640nMCHEMBL_ACT_19243010
PTGS16.13IC50740nMCHEMBL_ACT_19307255
DRD36.09AC50810nMCHEMBL_ACT_25193300
PTGS16.07IC50856nMCHEMBL_ACT_7725365
DRD25.93AC501180nMCHEMBL_ACT_25140102
SHMT25.71IC501950nMCHEMBL_ACT_19333075
PTGS15.66IC502200nMCHEMBL_ACT_25650362
CYP2C195.6Potency2512nMCHEMBL_ACT_4006373
CHRM15.48AC503300nMCHEMBL_ACT_25135219
MAPK15.3Potency5012nMCHEMBL_ACT_4541651
P159175.3Potency5012nMCHEMBL_ACT_4675116
HTR2C5.08AC508300nMCHEMBL_ACT_25131582
Q9F4F75.05Potency8912nMCHEMBL_ACT_4376581

Target pathways

Aggregated over 3 target gene(s): PTGS1, PTGS2, EPHX2.

Top Reactome pathways

12 total, by targets touching each:

PathwayTargetsGenes
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)2PTGS1, PTGS2
COX reactions1PTGS1
Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)1EPHX2
Synthesis of 15-eicosatetraenoic acid derivatives1PTGS2
Interleukin-10 signaling1PTGS2
Interleukin-4 and Interleukin-13 signaling1PTGS2
Biosynthesis of DHA-derived SPMs1PTGS2
Biosynthesis of EPA-derived SPMs1PTGS2
Biosynthesis of maresins1EPHX2
Biosynthesis of DPAn-3 SPMs1PTGS2
Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives1PTGS2
Peroxisomal protein import1EPHX2

Dominant GO biological processes

GO termTargets
lipid metabolic process3
prostaglandin biosynthetic process2
response to oxidative stress2
regulation of blood pressure2
cyclooxygenase pathway2
regulation of cell population proliferation2
long-chain fatty acid biosynthetic process2
fatty acid metabolic process2
fatty acid biosynthetic process2
prostaglandin metabolic process2
prostanoid biosynthetic process2
cellular oxidant detoxification2
embryo implantation1
response to nematode1
response to selenium ion1

Indications & clinical

Indications

4 indications (4 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
rheumatic disorder4MONDO:0005554EFO:0005755
rheumatoid arthritis4MONDO:0008383EFO:0000685
juvenile idiopathic arthritis4MONDO:0011429EFO:0002609
osteoarthritis4MONDO:0005178MONDO:0005178

Clinical trials

Total trials: 1.

Phase distribution

PhaseTrials
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT03350386PHASE1COMPLETEDDrug-drug Interaction Study of FYU-981 and Oxaprozin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

418 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
FulvestrantChEMBL + PubChemPhase 4 (approved)EPHX2, PTGS2
REGORAFENIBChEMBL + PubChemPhase 4 (approved)EPHX2, PTGS1
3,3’,4’,5-TETRACHLOROSALICYLANILIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
ACEMETACINChEMBLPhase 4 (approved)PTGS1, PTGS2
ASPIRINChEMBLPhase 4 (approved)PTGS1, PTGS2
BROMFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPSAICINChEMBLPhase 4 (approved)PTGS1, PTGS2
CAPTOPRILChEMBLPhase 4 (approved)PTGS1, PTGS2
CARPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
CELECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
CIANIDANOLChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXIBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DEXKETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
DICLOFENACChEMBLPhase 4 (approved)PTGS1, PTGS2
DIETHYLSTILBESTROLChEMBLPhase 4 (approved)PTGS1, PTGS2
DOXORUBICINChEMBLPhase 4 (approved)PTGS1, PTGS2
ESFLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
ETODOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
ETORICOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
FLURBIPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
GLAFENINEChEMBLPhase 4 (approved)PTGS1, PTGS2
HEXACHLOROPHENEChEMBLPhase 4 (approved)PTGS1, PTGS2
IBUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
INDOMETHACINChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
KETOROLACChEMBLPhase 4 (approved)PTGS1, PTGS2
LEVODOPAChEMBLPhase 4 (approved)PTGS1, PTGS2
LOXOPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
LUMIRACOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
MECLOFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MEFENAMIC ACIDChEMBLPhase 4 (approved)PTGS1, PTGS2
MELOXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
MOFEZOLACChEMBLPhase 4 (approved)PTGS1, PTGS2
MONOBENZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
NAPROXENChEMBLPhase 4 (approved)PTGS1, PTGS2
NIMESULIDEChEMBLPhase 4 (approved)PTGS1, PTGS2
OMADACYCLINEChEMBLPhase 4 (approved)PTGS1, PTGS2
PIROXICAMChEMBLPhase 4 (approved)PTGS1, PTGS2
PRIMAQUINEChEMBLPhase 4 (approved)PTGS1, PTGS2
RANITIDINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ROFECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
SELINEXORChEMBLPhase 4 (approved)PTGS1, PTGS2
SORAFENIBChEMBLPhase 4 (approved)EPHX2, PTGS2
SUPROFENChEMBLPhase 4 (approved)PTGS1, PTGS2
TEGASERODChEMBLPhase 4 (approved)PTGS1, PTGS2
TELOTRISTATChEMBLPhase 4 (approved)PTGS1, PTGS2
TOLMETINChEMBLPhase 4 (approved)PTGS1, PTGS2
TROGLITAZONEChEMBLPhase 4 (approved)PTGS1, PTGS2
VALDECOXIBChEMBLPhase 4 (approved)PTGS1, PTGS2
VORTIOXETINEChEMBLPhase 4 (approved)PTGS1, PTGS2
ZILEUTONChEMBLPhase 4 (approved)EPHX2, PTGS2
CURCUMINChEMBLPhase 3PTGS1, PTGS2
QUERCETINChEMBLPhase 3EPHX2, PTGS2
RESVERATROLChEMBLPhase 3PTGS1, PTGS2
CIMICOXIBChEMBLPhase 2PTGS1, PTGS2
DERACOXIBChEMBLPhase 2PTGS1, PTGS2
ENOFELASTChEMBLPhase 2PTGS1, PTGS2
FIROCOXIBChEMBLPhase 2PTGS1, PTGS2
FLUFENAMIC ACIDChEMBLPhase 2PTGS1, PTGS2
LICOFELONEChEMBLPhase 2PTGS1, PTGS2

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot